Friday, 27 May, 2022
HomeHIV/AIDS

HIV/AIDS

The top treatment stories out of AIDS 2020 conference

AIDS 2020, the 23rd International AIDS Conference was held virtually this year due to social distancing and the coronavirus and Aidsmap has selected the top treatment...

PrEP adherence demonstrated with urine tenofovir novel immunoassay

A novel immunoassay that measures urine tenofovir levels has high predictive utility and may adequately determine pre-exposure prophylaxis (PrEP) adherence and predict HIV protection,...

Follow-up finds dolutegravir use at conception not tied to neural tube defects in infants

Contradicting 2018 interim findings that dolutegravir use in pregnancy increased the risk of the rare birth defects, a Botswana follow-up study found no significant difference...

NEJM: Review of some 23rd International AIDS Conference highlights

Long-acting injectable cabotegravir is superior to TDF/FTC for pre-exposure prophylaxis in MSM and transgender women: Sure, we’ve known some of these results of HPTN...

Recycling tenofovir better than switch to second-line zidovudine

Retaining tenofovir after the failure of first-line treatment rather than replacing it with zidovudine was associated with better retention in care, better adherence and...

Injectable PrEP superior to oral PrEP in clinical trial

PrEP administered as an injection every eight weeks was more effective in preventing HIV than oral PrEP in gay and bisexual men and transgender...

Depo Provera associated with doubled bone loss in women starting ARVs

Use of the injectable hormonal contraceptive Depo Provera was associated with a doubling of bone loss in young women starting antiretroviral treatment containing tenofovir...

Introduction of PrEP reduces infections in women

The introduction of PrEP into a large study that was designed to find out if contraceptives increased the risk of HIV in women allowed...

PrEP success in Kenya and Uganda

A large cluster-randomised study which offered intensified healthcare, including PrEP, to 16 communities in Kenya and Uganda has reported a 74% reduction in HIV...

Islatravir keeps viral load suppressed

Islatravir, the first nucleoside reverse transcriptase translocation inhibitor, plus the non-nucleoside reverse transcriptase inhibitor doravirine (Pifeltro) kept viral load suppressed for 48 weeks with...

Rapid weight gain for people with HIV switching to tenofovir alafenamide

People who switched to tenofovir alafenamide (TAF) from the previous version of tenofovir (tenofovir disoproxil fumarate – TDF) experienced rapid weight gain regardless of...

Weight gain risk for people taking dolutegravir-based ARVs

People taking dolutegravir-based antiretroviral treatment have a substantially higher risk of becoming overweight or obese compared to other people with HIV and almost one...

Systemic TB treatment not superior to test guided treatment for HIV patients

In areas of sub-Saharan Africa and Asia, most HIV-infected patients present for care after already being severely immuno-compromised. After the initiation of antiretroviral therapy...

Infants newly diagnosed with HIV show high levels of resistance to ARVs

Pre-treatment drug resistance data for infants newly diagnosed with HIV from nationally representative surveys conducted between 2011 and 2016 in nine sub-Saharan African countries...

FDA paediatric version of dolutegravir to treat children

The US Food and Drug Administration (FDA) granted a new indication to a paediatric version of dolutegravir (Tivicay PD, ViiV Healthcare) tablets for oral...

US study finds PrEP regimen works

New data from Kaiser Permanente in San Francisco show that on-demand pre-exposure prophylaxis (PrEP) taken before and after sex – known as PrEP 2-1-1...

Recruitment to HIV trials 'not representative'

Recruitment to clinical trials that lead to the licensing of antiretroviral drugs is not representative of the global HIV pandemic, Aidsmap reports an international...

Long-acting ARV given as two monthly injectable PrEP protects against HIV

It’s not an Aids vaccine but it may be the closest thing to one so far. A long-acting antiretroviral drug given as an injection...

COVID-19 disruption of ARV treatments could double HIV deaths

A synthesis of five different studies that model the effect of a three- or six-month interruption of HIV services across sub-Saharan Africa finds that...

HIV-1 salvage therapy can omit NRTIs and remain efficacious and safe

People with HIV-1 infection (PWHIV) who have virologic failure can safely omit nucleoside reverse transcriptase inhibitors (NRTIs) in new regimens that include more than...

Review shows high prevalence of PTSD in people living with HIV

There is a high prevalence of post-traumatic stress disorder (PTSD) in people living with HIV, according to the first comprehensive systematic review and meta-analysis...

Paclitaxel plus ART shows superiority in treatment of advanced HIV-related Kaposi sarcoma

Intravenous paclitaxel plus antiretroviral therapy (ART) has clear advantages over alternative chemotherapy regimens for the treatment of advanced HIV-related Kaposi sarcoma in low- and...

Delaying treatment changes costs lives — SA study

Promptly switching antiretroviral therapy (ART) when individuals have viral rebound saves lives, Aidsmap reports an important study has found. Delayed switching more than doubled...

Integrase inhibitor-based ARV regimen reduces CVD risk in people with HIV

The risk of a serious cardiovascular event is reduced by a fifth in people taking an integrase inhibitor-based antiretroviral regimen compared to alternative drugs....

COVID-19 curtails HIV and immunotherapy efficacy trials

During the COVID-19 crisis, a number of the ongoing worldwide HIV vaccine and immunotherapy efficacy trials are being paused or curtailed, reports Aidsmap. The HIV...

Spanish study finds little symptomatic or recovery difference in HIV COVID-19 patients

The first cases of COVID-19 identified in people living with HIV in Barcelona’s main hospital do not differ from the rest of the population...

Depressive disorders under-recognised and under-treated in people with HIV/Aids

People living with HIV/Aids are at increased risk of depressive disorders. But all too often, these conditions go unrecognised or untreated, suggests a literature...

PrEP protecting against HIV and hepatitis B – study

A retrospective cohort study of gay and bisexual men attending sexual health clinics in Japan shows that taking HIV pre-exposure prophylaxis (PrEP) not only...

Dolutegravir associated with hyperglycaemia in people switching first-line ART in Uganda

Hyperglycaemia was reported in Uganda among people switching first-line regimens to dolutegravir-based antiretroviral treatment (ART), in a letter to Lancet HIV, published online 24...

Adherence clubs help reduce viral load in post-partum SA women living with HIV

Adherence clubs were linked to a 30% reduction in high viral load among postpartum South African women living with HIV, Aidsmap reports the Conference...

Key risk factors for the emergence of renal dysfunction

Age over 50 years and pre-existing kidney function are the risk factors for the emergence of renal dysfunction while taking PrEP, according to data...

New approaches to dosing newborns with abacavir

8mg/kg of abacavir given twice daily to normal- and low-birth-weight new-borns with HIV in South Africa was safe and effective according to presentations in...

2 studies look at potential weight gain for women taking dolutegravir

Women with HIV gained significantly more weight in the year after giving birth if they were taking dolutegravir rather than efavirenz, Aidsmap reports two...

Trial shows safety and efficacy of ARV combinations in pregnancy

Dolutegravir-based antiretroviral treatment was associated with a higher rate of undetectable viral load at delivery in pregnant women, results of the IMPAACT 2010 trial...

Community-based treatment superior to clinic-based care in SA

Starting antiretroviral treatment on the day of diagnosis in a community setting and picking up medication from a mobile van resulted in superior rates...

TasP suppresses new HIV infections among gay and bisexual men in Australia

HIV treatment as prevention, as measured in community-level viral suppression, was strongly associated with a large drop in the number of new HIV infections...

Trial looks at community-based multi-month dispensing of ARVS

Dispensing antiretroviral drugs to people with suppressed viral load every six months is just as effective as dispensing medication every three months, a study...

Study results support clinical evaluation of GS-6207 as a long-acting ARV agent

A phase Ib study of Gilead Sciences' long-acting HIV-1 capsid inhibitor GS-6207 in people living with HIV demonstrated the drug’s potent antiviral activity, as...

African study on PrEP uptake and adherence

An interim survey of PrEP uptake and adherence in the SEARCH study in Kenya and Uganda, has found that just over a quarter of...

British HIV Association issues statement on COVID-19

Last week the British HIV Association (BHIVA), which represents medical professionals working in HIV in the UK, issued a statement about the new coronavirus...